biostudies-literatureKomura KNaito Foundationthe Kenzo Suzuki Memorial FoundationJapanese Urological AssociationNational Cancer Center Research and Development FundsTakeda Science FoundationJapan Agency for Medical Research and DevelopmentJapan Society for the Promotion of Science185https://www.ebi.ac.uk/biostudies/studies/S-EPMC10657138biostudies-literatureUnknown22(1)<h4>Background</h4>Currently, only limited knowledge is available regarding the phenotypic association between fibroblast growth factor receptor 3 (FGFR3) alterations and the tumor microenvironment (TME) in bladder cancer (BLCA).<h4>Methods</h4>A multi-omics analysis on 389 BLCA and 35 adjacent normal tissues from a cohort of OMPU-NCC Consortium Japan was retrospectively performed by integrating the whole-exome and RNA-sequence dataset and clinicopathological record. A median follow-up duration of all BLCA cohort was 31 months.<h4>Results</h4>FGFR3 alterations (aFGFR3), including recurrent mutations and fusions, accounted for 44% of non-muscle invasive bladder cancer (NMIBC) and 15% of muscle-invasive bladder cancer (MIBC). Within MIBC, the consensus subtypes LumP was significantly more prMolecular cancerThe Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.PMC106571382020-A-2 and 2023-S-621H0482821H03070JP22jm0210085, JP22am0401007, and JP22ym0126804 (21-A-22)Tsutsumi TUra AHayashi TOhno TTakahara KNakamori KTaniguchi KTanaka TInamoto TTsujino TNishimura KTokushige SIshida MShiraishi YHirosuna KAzuma HYoshikawa YKomura KHirose YKonuma TYoshimi ATakai TKinoshita SAjiro MOno FMaenosono RYamazaki SfalseThe Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.<h4>Background</h4>Currently, only limited knowledge is available regarding the phenotypic association between fibroblast growth factor receptor 3 (FGFR3) alterations and the tumor microenvironment (TME) in bladder cancer (BLCA).<h4>Methods</h4>A multi-omics analysis on 389 BLCA and 35 adjacent normal tissues from a cohort of OMPU-NCC Consortium Japan was retrospectively performed by integrating the whole-exome and RNA-sequence dataset and clinicopathological record. A median follow-up duration of all BLCA cohort was 31 months.<h4>Results</h4>FGFR3 alterations (aFGFR3), including recurrent mutations and fusions, accounted for 44% of non-muscle invasive bladder cancer (NMIBC) and 15% of muscle-invasive bladder cancer (MIBC). Within MIBC, the consensus subtypes LumP was significantly more pr2023-01-01T00:00:00Z2023 Nov2026-05-29T08:07:56.113Z2025-04-06T01:23:54.989ZS-EPMC106571383798052810.1186/s12943-023-01897-6